|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
48.950 -1.300 (-2.587%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 2,540,432 | 58.214% | 3,524,143 | 2,364,445 | 1,552,486 | 1,190,479 |
| Cost of Sales | (447,192) | 75.575% | (577,006) | (369,205) | (198,149) | (183,410) |
| Gross Profit | 2,093,240 | 54.941% | 2,947,137 | 1,995,240 | 1,354,337 | 1,007,069 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (490) | -- | 700 | (614) | (326) | 2,479 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 1,155,190 | 48.945% | 1,745,089 | 1,177,749 | 972,917 | 973,242 | |
| Taxation | (174,640) | 59.401% | (296,887) | (176,163) | (144,785) | (146,757) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 2,614 | 185.060% | 3,551 | 439 | 0 | (35) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 983,164 | 47.414% | 1,451,753 | 1,002,025 | 828,132 | 826,450 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (38,937) | 64.284% | (47,379) | (13,138) | (9,408) | (9,882) |
| Depreciation & Amortisation | 20,851 | 23.605% | 34,175 | 27,628 | 24,210 | 22,291 |
| Directors' Emoluments | -- | -- | 16,596 | 14,161 | 13,099 | 2,752 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 99.000 | 47.761% | 149.000 | 99.000 | 83.000 | -- |
| DPS (cts) | 0.000 | -- | 89.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | 59.732% | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 1.687 | 1.325 | 0.710 | -- |
| NBV per share ($) | 5.806 | -- | 4.384 | 2.848 | -- | -- |
| Remarks: | Real time quote last updated: 30/12/2024 11:57 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 983,164 |
| %Change | 47.414% |
| EPS / (LPS) | RMB 0.990 |
| NBV Per Share (¥) | RMB 5.806 |